Kaliumchloride - Glucose B. Braun (Potassium Chloride, Glucose)

Potassium chloride dissociates after infusion, releasing potassium ions that are taken up by cells, thereby raising serum potassium concentrations. The accompanying glucose stimulates insulin release, which further drives potassium into cells and supplies immediate metabolic energy.

The dose is individualized by the prescribing clinician based on the patient’s current serum potassium, glucose levels, renal function, and overall fluid balance. The healthcare professional calculates the required volume and infusion rate to achieve target laboratory values.

Safety data for this specific intravenous formulation in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike plain potassium chloride solutions, Kaliumchloride - Glucose B. Braun combines potassium with glucose, offering both electrolyte correction and an immediate energy source. This dual composition can reduce the need for separate dextrose infusions and may improve cellular potassium uptake through insulin‑mediated mechanisms.

Store the solution at ambient temperature, below 25 °C, in its original packaging. Protect it from direct sunlight, moisture, and extreme temperatures. Do not freeze the product, and inspect the container for any leaks or particulate matter before use.

The product is administered intravenously, typically via a controlled infusion pump or gravity drip. The infusion rate is set according to the patient’s clinical condition, laboratory results, and physician orders, with continuous monitoring of vital signs and serum electrolytes.

The most critical risks include hyperkalemia, which can cause life‑threatening cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and marked hyperglycemia that may lead to osmotic diuresis or metabolic complications. Prompt monitoring and dose adjustment are essential.

Patients with known hypersensitivity to potassium chloride or glucose, those with severe hyperkalemia, uncontrolled diabetes with high baseline glucose, or individuals receiving incompatible IV medications (e.g., calcium solutions) should not be given this product without careful risk assessment.